Pyxis Oncology shares are trading lower after the company announced updated data from its ongoing global Phase 1 monotherapy study evaluating MICVO in patients with 2L+ R/M head and neck squamous cell carcinoma.

Benzinga Newsdesk www.benzinga.com Negative 96.7%

Neg 96.7% Neu 0% Pos 0%

Comments

No comments yet. Be the first!